Article ID Journal Published Year Pages File Type
5816530 Phytomedicine 2014 8 Pages PDF
Abstract
Results suggest that the primary effect of (+)-PA is inhibition of FASN activity. Synergistic effects with lapatinib were seen only in SK-BR-3 cells, and not T-47D cells, further supporting the notion that (+)-PA acts by inhibiting FASN with secondary effects on HER2 expression and signalling. (+)-PA could therefore be a suitable agent for further testing, alone or in combination treatment against HER2-overexpressing breast cancer.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Clinical Biochemistry
Authors
, , , , , ,